Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Anthony S Wierzbicki

Anthony S Wierzbicki is consultant (honorary professor) in metabolic medicine/chemical pathology at the Department of Chemical Pathology, Guy’s and St Thomas’ Hospitals, London, UK.

Recent stories

  • Statin myopathy stain showing muscle fibres in varying stages of necrosis, phagocytes and regeneration

    Statins: general safety profile and association with myopathySubscription

    11 MAY 2016Comments (1)

    Statin therapy has demonstrated remarkable efficacy in reducing mortalities associated with cardiovascular diseases through preventing myocardial infarction and ischaemic stroke. Despite the proven benefits of statins in this context, there are growing concerns among patients and physicians on the safety of short-term and long-term use and their adverse effects, especially muscle toxicity, resulting in non-adherence and withdrawal of the treatment. Reports and publications on

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.